Imazodan hydrochloride

CAS No. 89198-09-4

Imazodan hydrochloride( —— )

Catalog No. M34282 CAS No. 89198-09-4

Imazodan hydrochloride (CI-914 HCl) is a potent and selective type III phosphodiesterase inhibitor used in the treatment of chronic congestive heart failure.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 686 In Stock
10MG 938 In Stock
25MG 1444 In Stock
50MG 1841 In Stock
100MG 2325 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Imazodan hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Imazodan hydrochloride (CI-914 HCl) is a potent and selective type III phosphodiesterase inhibitor used in the treatment of chronic congestive heart failure.
  • Description
    Imazodan hydrochloride (CI-914 HCl) is a potent and selective type III phosphodiesterase inhibitor used in the treatment of chronic congestive heart failure.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    89198-09-4
  • Formula Weight
    276.72
  • Molecular Formula
    C13H13ClN4O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cl.O=C1NN=C(C=2C=CC(=CC2)N3C=NC=C3)CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Triflusal

    Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981.

  • Tadalafil

    Tadalafil is a potent phosphodiesterase-5 (PDE5) inhibitor (IC50=1 nM).

  • Mirodenafil

    Mirodenafil is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.The pharmacoki-netics of mirodenafil were not significantly altered by this concurrent administration. Mirodenafil (50 or 100 mg), obviously improved erectile function and was well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities.